Integrative Structural and Network Analysis Identifies CDK9 as a Candidate Therapeutic Target in Short-Term Survivor High-Grade Serous Ovarian Cancer
Abstract
Background: High-grade serous ovarian cancer (HGSC) exhibits marked clinical heterogeneity, with Short-Term (ST) survivors demonstrating intrinsic resistance to standard chemotherapy and poor outcomes. Understanding tumor-intrinsic transcriptional vulnerabilities in ST-HGSC represents a critical unmet need for precision therapeutic development. This study integrates structural bioinformatics, network topology analysis, and pharmacogenomics to identify druggable master regulators sustaining the aggressive ST phenotype.Methods: We analyzed transcriptomic data from Kotnik et al. (2023) comparing ST and Long-Term (LT) HGSC survivors, identifying 325 significantly upregulated differentially expressed genes (DEGs) in the ST cohort (log₂FC >1.5, adjusted P0.4), and master regulatory hubs were identified using the Maximal Clique Centrality (MCC) algorithm in CytoHubba. Survival analysis was performed using Kaplan-Meier Plotter (n=1,435 serous ovarian cancer patients). Functional enrichment of hub neighborhoods was conducted using NetworkSuite v2.1 (Sequensolutions), integrating Gene Ontology, Reactome, WikiPathways, and KEGG databases. Pharmacogenomic repurposing was performed using L1000CDS2, and drug-target interactions were validated through structural analysis.Results: AlphaFold2 modeling demonstrated that ESR1-CCDC170 retains the DNA-binding domain (pLDDT >85) but completely lacks the C-terminal ligand-binding domain, providing structural evidence for endocrine therapy resistance. Network analysis identified Cyclin-Dependent Kinase 9 (CDK9) as the top-ranked hub (degree=17, highest MCC score), exhibiting both high connectivity and betweenness centrality. Survival analysis confirmed that high CDK9 expression significantly predicted poor overall survival (median OS: 42.5 vs 51.2 months; HR=1.28, 95% CI: 1.10-1.51; log-rank P=0.0088). Functional enrichment of CDK9's 17 first-degree interactors revealed profound overrepresentation in RNA Polymerase II transcriptional elongation pathways (FDR
Fields of Study & Subjects
Ovarian cancer diagnosis and treatment
BRCA gene mutations in cancer
Cancer-related molecular mechanisms research
Publication details
- Volume
- 9
- Issue
- 1
- Pages
- 111–132
- Publication date
- 24 February 2026
- Language
- EN